Inflammation and Metabolic Syndrome

The Metabolic Syndrome: Second Edition

Volumn , Issue , 2011, Pages 210-228

  Devaraj, Sridevi ^a,b   Siegel, David ^a,c,d   Jialal, Ishwarlal ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adipokines; Cardiovascular risk; CRP; Cytokines; Diabetes; Inflammation; Metabolic syndrome

Indexed keywords

EID: 84876800640     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444347319.ch13     Document Type: Chapter

References (113)

1. Alexander CM, Landsman PB, Teutsch SM, Haffner SM (2003). Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 52,1210-1214.
2. Aronson D, Sella R, Sheikh-Ahmad M, et al. (2004). The association between cardiorespiratory fitness and C-reactive protein in subjects with the metabolic syndrome. J Am Coll Cardiol, 44, 2003-2007.
3. Asano T, Sakosda H, Fujishiro M, et al. (2006). Physiological significance of resistin and resistin-like molecules in the inflammatory process and insulin resistance. Curr Diabetes Rev, 2, 449-454.
4. Assmann G, Nofer JR, Schulte H (2004). Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. Endocrinol Metab Clin North Am, 33, 377-392.
5. Attie AD, Scherer PE (2009). Adipocyte metabolism and obesity. J Lipid Res, 50 Suppl: S395-S399.
6. Axelsson J, O'Byrne SM, Blaner WS, Carrero JJ, Bruchfeld A, Heimbürger O, Bárány P, Lindholm B, Stenvinkel P (2008). Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5. Am J Nephrol, 29,447-453.
7. Ballantyne CM, Hoogeveen RC, Bang H, et al. (2005). Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med, 165, 2479-2484.
8. Bełtowski J, Jamroz-Wis'niewska A, Widomska S. Adiponectin and its role in cardiovascular diseases (2008). Cardiovasc Hematol Disord Drug Targets, 8, 7-46.
9. Beltowski J (2006). Leptin and atherosclerosis. Atherosclerosis, 189, 47-60.
10. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J; ACTFAST investigators (2007). Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J, 153, 881-888.
11. Bose T, Alvarenga JC, Tejero ME, Voruganti VS, Proffitt JM, Freeland-Graves JH, Cole SA, Comuzzie AG (2009). Association of monocyte chemoattractant protein-1 with adipocyte number, insulin resistance and liver function markers. J Med Primatol. 38(6):418-424.
12. Calabrò P, Limongelli G, Pacileo G, Di Salvo G, Golino P, Calabrò R (2008). The role of adiposity as a determinant of an inflammatory milieu. J Cardiovasc Med (Hagerstown), 9, 450-460.
13. Chandran M, Phillips SA, Ciaraldi T, Henry RR (2003). Adiponectin: more than just another fat cell hormone? Diabetes Care, 26, 244-250.
14. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A; PROactive Study Group (2004). The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care, 27, 1647-1653.
15. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS (2004). Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care, 27, 2654-2660.
16. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C (2004). Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. J Am Coll Cardiol, 44, 152-158.
17. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS (2005). Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res, 46, 2347-2355.
18. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T (1998) Tumor necrosis factor TNFalpha in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab, 83, 2907-2910.
19. Devaraj S, Jialal I (2000). Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med, 29, 790-717.
20. Devaraj S, Singh U, Jialal I (2009). Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol, 20, 182-189.
21. Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel PJ, Jialal I (2008). CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new l aboratory-based biomarkers. Am J Clin Pathol, 129, 815-822.
22. Devaraj S, Torok N, Dasu MR, Samols D, Jialal I (2008). Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol, 28, 1368-1374.
23. Diabetes Prevention Program (DPP) Research Group (2002) The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care, 25, 2165-2171.
24. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279, 1615-1622.
25. Dubey L, Hesong Z (2006). Role of leptin in atherogenesis. Exp Clin Cardiol, 11, 269-275.
26. Eckel RH, Grundy SM, Zimmet PZ (2005). The metabolic syndrome. Lancet, 365, 1415-1428.
27. Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G, Giugliano D (2003). Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab, 88, 1055-1058.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285, 2486-2497.
29. Fadini GP, Agostini C, Avogaro A (2005). Endothelial progenitor cells and vascular biology in diabetes mellitus: current knowledge and future perspectives. Curr Diabetes Rev, 1, 41-58.
30. Fadini GP, Agostini C, Boscaro E, Avogaro A (2009). Mechanisms and significance of progenitor cell reduction in the metabolic syndrome. Metab Syndr Relat Disord, 7, 5-10.
31. Fasshauer M and Paschke R (2003). Regulation of adipocytokines and insulin resistance. Diabetologia, 46, 1594-1603.
32. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM (2004). Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 102, 42-47.
33. Festa A, D'Agostino R, Jr., Mykkanen L, Tracy R, Howard BV, Haffner SM (1999). Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol, 19, 605-610.
34. Fonseca VA, Diez J, McNamara DB (2004). Decreasing restenosis following angioplasty: the potential of peroxisome proliferator-activated receptor gamma agonists. Diabetes Care, 27, 2764-2766.
35. Ford ES (2005). Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care, 28, 2745-2749.
36. Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A, Helsing E, Trichopoulos D (1995). Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr, 61 (6 Suppl), 1402S-1406S.
37. Girman CJ, Rhodes T, Mercuri M, Pyörälä K, Kjekshus J, Pedersen TR, Beere PA, Gotto AM, Clearfield M; 4S Group and the AFCAPS/TexCAPS Research Group (2004). The metabolic syndrome and risk of major coronary events in the 4S and AFCAPS/TexCAPS study. Am J Cardiol, 93, 136-141.
38. Gómez-Ambrosi J, Frühbeck G (2005). Evidence for the involvement of resistin in inflammation and cardiovascular disease. Curr Diabetes Rev, 1, 227-234.
39. Gustafson B (2010). Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb, 17, 332-341.
40. Haffner S, Cassells HB (2003). Metabolic syndrome-a new risk factor of coronary heart disease? Diabetes Obes Metab, 5, 359-370.
41. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM (2002). Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care, 25, 2016-2021.
42. Hanley AJ, Festa A, D'Agostino RB Jr, Wagenknecht LE, Savage PJ, Tracy RP, Saad MF, Haffner SM (2004). Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes, 2004, 53, 1773-1781.
43. Hanson RL, Imperatore G, Bennett PH, Knowler WC (2002). Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes, 51, 3120-3127.
44. Heinrich PC, Castell JV, Andus T (1990). Interleukin-6 and the acute phase response. Biochem J, 265, 621-636.
45. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T (2003). Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med, 348, 593-600.
46. Hotamisligil GS (1993). Adipose expression of tumor necrosis factor: direct role in obesity-linked insulin resistance. Science, 259, 87-91.
47. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L (2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, 683-689.
48. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P (1998) Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord, 22, 312-317.
49. Jenkins DJ, Kendall CW, Marchie A, et al. (2003). Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA, 290, 502-510.
50. Jialal I, Devaraj S, Singh U, Huet BA (2010). Decreased number and impaired functionality of endothelial progenitor cells in subjects with metabolic syndrome: Implications for increased cardiovascular risk. Atherosclerosis, Feb 4, 211, 297-302.
51. Jialal I, Devaraj S (2001). Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol, 116 Suppl, S108-S115. Jialal I, Devaraj S (2009). Statin therapy for the metabolic syndrome: the evidence base. Metab Syndr Relat Disord, 7, 393-396.
52. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG (1996). Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation, 94, 2057-2063.
53. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB (1995). The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest, 95, 2111-2119.
54. Kim JY, van de Wall E, Laplante M, et al. (2007). Obesityassociated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest, 117, 2621-2637.
55. Koenig W, Khuseyinova N, Baumert J, Meisinger C (2008). Prospective study of high sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin Chem, 54, 335-342.
56. Kondo H, Shimomura I, Matsukawa Y, et al. (2002). Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes, 51, 2325-2328.
57. Kowalska I, Straczkowski M, Adamska A, et al. (2008). Serum retinol binding protein 4 is related to insulin resistance and nonoxidative glucose metabolism in lean and obese women with normal glucose tolerance. J Clin Endocrinol Metab, 93, 2786-2789.
58. Laaksonen DE, Lindstrom J, Lakka TA, et al. (2005). Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes, 54, 158-165.
59. Lago R, Gómez R, Lago F, Gómez-Reino J, Gualillo O (2008). Leptin beyond body weight regulation-current concepts concerning its role in immune function and inflammation. Cell Immunol, 252, 139-145.
60. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288, 2709-2716.
61. Lewis JG, Shand BI, Elder PA, Scott RS (2008). Plasma retinol-binding protein is unlikely to be a useful marker of insulin resistan. Diabetes Res Clin Pract, 80, e13-e15. Libby P, Ridker PM (2004). Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med, 116 Suppl 6A, 9S-16S. Libby P (2002). Inflammation in atherogenesis. Nature, 420, 868-874.
62. Linton MF, Fazio S (2003). Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord, 27 Suppl 3, S35-S40.
63. Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, Su TC, Chen CL, Yang WS (2008). Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci, 5, 565-576.
64. Martin SS, Qasim A, Reilly MP (2008). Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol, 52, 1201-1210.
65. Matarese G, Mantzoros C, La Cava A (2007). Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des, 13, 3676-3680.
66. Matsuzawa Y, Funashi T, Kihar S, Shimomura I (2004). Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol, 24:29-33.
67. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE (1994). Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes, 43, 104-109.
68. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM (2000). Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA, 283, 221-228.
69. Moller DE (2000). Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab, 11, 212-217.
70. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT (2000). Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation, 102, 2180-2184.
71. Oda E (2008). The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res, 31, 1283-1291.
72. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S. Diabetes Prevention Program Research Group (2005).The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med, 142, 611-619.
73. Pellme F, Smith U, FUnahashi T, Matsuzawa Y, Brekke H (2003). Circulating adiponectin levels are reduced in non-obese but insulin resistant first degree relatives of t2dm. Diabetes, 52, 1182-1186.
74. Pickup JC, Mattock MB, Chusney GD, Burt D (1997). NIDDM as a disease of the innate immune systemassociation of acute-phase reactants and interleukin-6 with metabolic syndrome. Diabetologia, 40, 1286-1292.
75. Pyorala K, Ballantyne CM, Gumbiner B (2004). Reduction of cardiovascular events by simvastatin in non-diabetic CHD with and without metabolic syndrome. Diabetes Care, 27, 1735-1740.
76. Rasouli N, Kern PA (2008). Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab, 93 (11 Suppl 1), S64-S73.
77. Ridker PM, Buring JE, Cook NR, Rifai N (2003). C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation, 107, 391-397.
78. Ridker PM, Danielson E, Fonseca FAH (2009). Reduction in CRP and LDL and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet, 373, 1175-1182.
79. Ridker PM, Glynn RJ, Hennekens CH (1998). C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation, 97, 2007-2011.
80. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 342, 836-843.
81. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 342, 836-843.
82. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E (1998). Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 98, 839-844.
83. Ridker PM, Wilson PW, Grundy SM (2004). Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation, 109, 2818-2825.
84. Ross R (1993).The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362, 801-809.
85. Ross R (1999). Atherosclerosis-an inflammatory disease. N Engl J Med, 340, 115-126.
86. Ryan AS, Nicklas BJ (2004). Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care, 27, 1699-1705.
87. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP (2000). Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol, 152, 897-907.
88. Sattar N, Gaw A, Scherbakova O (2003). Metabolic syndrome with and without CRP as a predictor of CHD and diabetes in WOSCOPS. Circulation, 108, 414-419.
89. Sattar N, Gaw A, Scherbakova O, et al. (2003). Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 108, 414-419.
90. Singh V, Deedwania P (2009). Reducing morbidity and mortality in high risk patients with statins. Vasc Hlth and Risk Mgmt, 5, 495-507.
91. Sugiura K, Tamakoshi K, Yatsuya H, et al. (2008). Contribution of adipocytokines to low-grade inflammatory state as expressed by circulating C-reactive protein in Japanese men: comparison of leptin and adiponectin. Int J Cardiol, 130(2):159-164.
92. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T (2007). Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab, 92, 2712-2719.
93. Tamura Y, Sugimoto M, Murayama T, et al. (2010). C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. J Atheroscler Thromb, 17, 219-228.
94. Tamura Y, Sugimoto M, Murayama T, Minami M, Nishikaze Y, Ariyasu H, Akamizu T, Kita T, Yokode M, Arai H (2010). C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. J Atheroscler Thromb. 17(3):219-228.
95. Tamura Y, Sugimoto M, Murayama T, et al. (2008). Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol, 28, 2195-2201.
96. Tateya S, Tamori Y, Kawaguchi T, Kanda H, Kasuga M (2010). An increase in the circulating concentration of monocyte chemoattractant protein-1 elicits systemic insulin resistance irrespective of adipose tissue inflammation in mice. Endocrinology. 151(3):971-979.
97. Tousoulis D, Andreou I, Antoniades C (2008). Role of inflammation and oxidative stress in endothelial progenitor cell function and mobilization: therapeutic implications for cardiovascular diseases. Atherosclerosis, 201, 236-247.
98. Tuomilehto J, Lindström J, Eriksson JG, et al. (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med, 344, 1343-1350.
99. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C (1989). Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism, 38, 913-915.
100. Van Exel E, Gussekloo J, de Craen AJ (2002). Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes, 51, 1088.
101. Vazquez LA, Pazos F, Berrazueta JR, Fernandez-Escalante C, Garcia-Unzueta MT, Freijanes J, Amado JA (2005). Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab, 90, 316-322.
102. Vozarova B, Weyer C, Hanson K, et al. (2001).Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001, 9, 414-417.
103. Vu JD, Vu JB, Pio JR, Malik S, Franklin SS, Chen RS, Wong ND (2005). Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol, 96, 655-658.
104. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N (2001). Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation, 104, 3052-3056.
105. Wang CH, Li SH, Weisel RD, Fedak WM, Dumont AS, Szmitko P, Li RK, Mickle AG, Verma S (2003). C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation, 107, 1783-1790.
106. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT (2004). Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol, 93, 362-365.
107. Watson T, Goon PK, Lip GY (2008). Endothelial progenitor cells, endothelial dysfunction, inflammation, and oxidative stress in hypertension. Antioxid Redox Signal, 10, 1079-1088.
108. Westerweel PE, Visseren FL, Hajer GR, et al. (2008). Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. Simvastatin/ezetimibe combination therapy. Eur Heart J, 29, 2808-2817.
109. Weyer C, Funahashi T, Tanaka S, et al. (2001). Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 86, 1930-1935.
110. Wozniak SE, Gee LL, Wachtel MS, Frezza EE (2009). Adipose Tissue: The New Endocrine Organ? A Review Article. Dig Dis Sci, 54, 1847-1856.
111. Yang RZ, Lee MJ, Hu H, Pollin TI, et al. (2006). Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med, 3, e287. Ye J (2009). Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond), 33, 54-66.
112. Yki-Järvinen H (2004). Thiazolidinediones. N Engl J Med, 351, 1106-1118.
113. Yudkin JS, Kumari M, Humphries SE, et al. (2000). Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis, 148, 209-214.